Dosage and usage of levacetylleucine

Levacetylleucine is a specific drug for the treatment of neurological symptoms of Niemann-Pick disease type C (NPC;rare disease). Its dosage regimen needs to be strictly individualized based on the patient's weight.

For patients weighing 35kg and above, the "2-1-1" dosage regimen is recommended, that is, 2g in the morning, 1g each in the afternoon and evening; patients 25-35kg take 1g three times a day; patients 15-25kg take 1g twice a day, morning and evening. This stepped dosing design is based on pharmacokinetic studies and ensures stable blood concentrations while minimizing the risk of adverse reactions. It is particularly important to note that female patients of childbearing age must confirm their non-pregnancy status before starting treatment and take reliable contraceptive measures throughout the treatment period.

There are special requirements for the preparation and administration of the drug: each 1.7g granule (containing 1g of active ingredient) needs to be mixed with 40ml of cold water, room temperature water, orange juice or almond milk, and must be taken within 30 minutes after stirring. This specific formulation method is to ensure optimal solubility and bioavailability of the drug, and the use of hot water or other liquid substitutions is strictly prohibited. Clinical observation shows that about 15% of patients may experience mild gastrointestinal discomfort. It is recommended to fix the daily medication time. If taken with a small amount of food, symptoms can be alleviated. For patients who have difficulty swallowing or require nasogastric feeding, the administration method should be adjusted under the guidance of a medical professional.

Therefore, it is necessary to regularly evaluate the improvement of neurological symptoms and adverse reactions during treatment, and adjust the dose according to the patient's response and tolerance, but the total daily dose should not exceed4g. It is worth noting that the drug needs to be used continuously for a long time to maintain its efficacy. Even if the symptoms improve, the drug should not be stopped without authorization.

Reference:https://reference.medscape.com/drug/aqneursa-levacetylleucine-4000455